本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

诺和诺德

54.37
-1.7200-3.07%
盘后54.600.2300+0.42%19:59 EDT
成交量:1,476.15万
成交额:7.97亿
市值:2,413.51亿
市盈率:13.84
高:54.44
开:53.88
低:53.54
收:56.09
52周最高:119.07
52周最低:45.05
股本:44.39亿
流通股本:31.88亿
量比:1.53
换手率:0.46%
股息:1.79
股息率:3.30%
每股收益(TTM):3.93
每股收益(LYR):3.15
净资产收益率:79.17%
总资产收益率:21.82%
市净率:9.76
市盈率(LYR):17.27

数据加载中...

公司资料

公司名字:
诺和诺德
交易所:
NYSE
成立时间:
1923
员工人数:
78387
公司地址:
Novo Alle 1,Bagsvaerd,Capital Region of Denmark,Denmark
邮编:
2880
传真:
- -
简介:
Novo Nordisk A/S成立于1989年,由两家丹麦公司Nordisk Gentofte A/S和Novo Industri A/S合并而成。该公司是一家全球医疗保健公司,也是糖尿病和肥胖症护理领域的全球领导者。该公司拥有广泛的糖尿病和肥胖症护理以及罕见疾病产品组合,包括用于治疗糖尿病和肥胖症的胰高血糖素样肽-1(GLP-1)受体激动剂、现代胰岛素和人胰岛素。

董事

名称
职位
Helge Lund
Chairman of the Board
Henrik Poulsen
Vice Chairman of the Board
Andreas Fibig
Independent Director
Christina Law
Independent Director
Laurence Debroux
Independent Director
Martin Mackay
Independent Director
Sylvie Gregoire
Independent Director
Elisabeth Dahl Christensen
Director
Kasim Kutay
Director
Liselotte Hyveled
Director
Mette Bojer Jensen
Director
Thomas Rantzau
Director

股东

名称
职位
Maziar Mike Doustdar
President, Chief Executive Officer
Karsten Munk Knudsen
Executive Vice President and Chief Financial Officer
Camilla Sylvest
Executive Vice President, Commercial Strategy and Corporate Affairs
David Moore
Executive Vice President, US Operations and Business Development
Henrik Wulff
Executive Vice President, Product Supply, Quality Assurance, Digital Data and Information Technology
Lars Fruergaard Jorgensen
Vice President, International Operations
Ludovic Helfgott
Executive Vice President, Rare Disease
Martin Holst Lange
Chief Scientific Officer
Tania Sabroe
Executive Vice President, People and Organisation